All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.

The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your AML Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
Visit:
ALL Hub

ALL Hub

GvHD Hub

GvHD Hub

Lupus Hub

Lupus Hub

Lymphoma Hub

Lymphoma Hub

MPN Hub

MPN Hub

Multiple Myeloma

Multiple Myeloma Hub

PsOPsA Hub

PsOPsA Hub

LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
Steering CommitteeAbout UsNewsletterContact
TypesTherapeuticsCongressesTrialsExpert OpinionsDRUG UPDATES
2020-07-21T23:00:00.000Z

What is the optimal gene panel to be assessed for risk stratification?

By Alia Mohamed, Lars Bullinger, Amalia Zachariadis
Jul 21, 2020
Share:

Bookmark this article

The AML Hub was pleased to speak to Lars Bullinger, Charité – Universitätsmedizin Berlin, Berlin, DE, during the European School of Haematology (ESH) 2nd How to Diagnose and Treat: Acute Leukaemia meeting. We asked, What is the optimal gene panel to be assessed for risk stratification?

Lars Bullinger states that the optimal gene panel for risk stratification should comprise genes that aid in the diagnosis, characterization, and monitoring of the disease. The ideal gene panel would include up to 50 genes, such as IDH1/2 genes, and comprise the six molecular markers that are described in the European LeukemiaNet guidelines.

What is the optimal gene panel to be assessed for risk stratification?

More about...
AML-related mutationsASXL1CEBPAESH 2020FLT3-ITDFLT3-TKDIDH1IDH1 inhibitorsIDH2IDH2 inhibitorsNPM1RUNX1TP53

Related articles

Add bookmark

Establishing precision medicine and novel molecular target therapies in Japanese patients with AML

The (HM)-SCREEN-Japan 01 program aims to establish precision medicine and novel molecular target therapies in Japanese patients with AML.

May 31, 2019
Add bookmark

Establishing precision medicine and novel molecular target therapies in Japanese patients with AML

The (HM)-SCREEN-Japan 01 program aims to establish precision medicine and novel molecular target...

May 31, 2019
Add bookmark

Spectrum and prognostic relevance of driver gene mutations in Acute Myeloid Leukemia

K H. Metzeler et al. investigated the spectrum of recurrent driver gene mutations in 664 previously untreated AML patients who received intensive induction...

Aug 16, 2016
Add bookmark

Spectrum and prognostic relevance of driver gene mutations in Acute Myeloid Leukemia

K H. Metzeler et al. investigated the spectrum of recurrent driver gene mutations in 664 previously untreated AML...

Aug 16, 2016

Newsletter

Subscribe to get the best content related to AML delivered to your inbox